Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1992-6-25
|
| pubmed:abstractText |
From 1981 to 1987, 81 patients with localized, unresectable carcinoma of the pancreas were treated at Thomas Jefferson University Hospital with a combination of intraoperative Iodine-125 implantation, external beam radiation, and peri-operative systemic chemotherapy. Fifty patients had Stage II disease and 31 patients had Stage III disease. Radioactive Iodine-125 seeds were implanted intraoperatively into the tumor to deliver a minimum peripheral dose of 12,000 cGy over one year. This was followed by external beam radiation (50-55 Gy) and systemic chemotherapy (5-FU, Mitomycin-C +/- CCNU). Incidence of peri-operative mortality was 5% (4/81). Early morbidity was observed in 34% of patients and late complications in 32%. A median survival of 12 months and 2- and 5-year survival rates of 21% and 7% were observed. The determinate 2- and 5-year survival rates were 28% and 13%, respectively. The overall 2- and 5-year survival rates with Stage II disease were 27% and 8% and for Stage III disease, 13% and 3%, respectively (p less than 0.05). The determinate 2- and 5-year survival rates were 34% and 19% for Stage II and 19% and 5% for Stage III disease, respectively (p = 0.08). Local control of disease was achieved in 71% of patients. This combined modality approach appears to have achieved satisfactory local control of primary cancer and long term survival of selected patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0360-3016
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
23
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
305-11
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:1587751-Adenocarcinoma,
pubmed-meshheading:1587751-Adult,
pubmed-meshheading:1587751-Aged,
pubmed-meshheading:1587751-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1587751-Brachytherapy,
pubmed-meshheading:1587751-Combined Modality Therapy,
pubmed-meshheading:1587751-Fluorouracil,
pubmed-meshheading:1587751-Humans,
pubmed-meshheading:1587751-Iodine Radioisotopes,
pubmed-meshheading:1587751-Lomustine,
pubmed-meshheading:1587751-Male,
pubmed-meshheading:1587751-Middle Aged,
pubmed-meshheading:1587751-Mitomycin,
pubmed-meshheading:1587751-Pancreatic Neoplasms,
pubmed-meshheading:1587751-Retrospective Studies,
pubmed-meshheading:1587751-Survival Analysis,
pubmed-meshheading:1587751-Survival Rate,
pubmed-meshheading:1587751-Time Factors
|
| pubmed:year |
1992
|
| pubmed:articleTitle |
Long-term results of combined modality treatment with I-125 implantation for carcinoma of the pancreas.
|
| pubmed:affiliation |
Department of Radiation Oncology and Nuclear Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107.
|
| pubmed:publicationType |
Journal Article
|